Summary of Metabolic Septic Shock Sub-Phenotypes, Stability Over Time and Association with Clinical Outcome
Abstract Summary: Antcliffe et al. examined metabolic sub-phenotypes in septic shock using metabolomic data from two clinical trials (LeoPARDS and VANISH). They identified three distinct metabolic clusters, primarily characterized by lipid metabolite levels, especially lysophospholipids. Persistence in low lysophospholipid clusters correlated significantly with increased mortality. These findings suggest metabolic monitoring could aid in identifying high-risk septic shock patients who might benefit from tailored therapeutic interventions.
Key Points:
-
Study Design and Cohorts: The analysis included data from two randomized trials (LeoPARDS and VANISH), involving 663 patients and 1,895 serum samples, using nuclear magnetic resonance (NMR) spectroscopy and ultra-high performance liquid chromatography mass spectrometry (UHPLC-MS) for metabolite profiling.
-
Metabolic Sub-Phenotypes Identified: Three distinct metabolic clusters were robustly identified using machine learning techniques, characterized mainly by varying levels of lipid metabolites, notably lysophospholipids and triglycerides.
-
Cluster Stability and Evolution: Initial cluster proportions changed significantly over time, with the metabolically favorable cluster (high lysophospholipid levels) becoming more prevalent and associated with improved survival outcomes.
-
Clinical Outcome Associations: Persistence in metabolically unfavorable clusters (characterized by low lysophospholipids) significantly correlated with higher mortality rates (LeoPARDS: OR 3.66, p=0.0001; VANISH: OR 4.13, p=0.03).
-
Inflammation and Protein Profiles: Low lysophospholipid clusters exhibited higher inflammatory protein levels, including IL-6, sTNFR1, and Ang-2, indicating greater inflammatory and endothelial dysfunction.
-
Gene Expression Insights: Differential gene expression analysis revealed distinct pathways enriched in the high triglyceride, low lysophospholipid cluster, notably related to cell division and immune response.
-
Metabolite Signatures: Lysophosphatidylcholines and triglycerides emerged as key discriminators of cluster membership, suggesting their potential as therapeutic targets or biomarkers.
-
Implications for Therapy: The findings imply potential therapeutic interventions, such as lysophospholipid supplementation, could benefit patients persistently in high-risk metabolic sub-phenotypes.
-
Limitations and Future Directions: The authors acknowledged study limitations, including targeted metabolite measurement constraints, potential confounding factors (medications, feed), and survivorship bias influencing longitudinal analyses.
-
Conclusion and Clinical Utility: Metabolic sub-phenotyping presents a promising approach to stratify septic shock patients, enhance prognostic accuracy, and guide personalized therapeutic strategies based on metabolic trajectories.
Conclusion: The study robustly establishes three distinct metabolic clusters in septic shock, highlighting the prognostic significance of metabolic trajectories. Persistent low lysophospholipid levels indicate poor outcomes, offering a novel approach for monitoring and potentially guiding personalized treatments in septic shock.
Watch the following video on :Pro-Con: Are Personalized Interventions in Sepsis Even Possible? (Session 7 – 2022 WSC Spotlight)” by World Sepsis Congress (WSC)
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
